Table 2.
Summary of patients’ clinical data and statistical analysis of correlation between mTOR expression and clinical features
| Number | mTOR– p-mTOR– |
mTOR + p-mTOR + |
p | ||
|---|---|---|---|---|---|
| Total | 31 | 23 26 |
8 5 |
||
| Sex | F/M | 14/17 | 10/13 11/15 |
4/4 3/2 |
1.00 0.47 |
| Age (years) | 1–6 / > 6 | 18/13 | 14/9 15/11 |
4/4 3/2 |
0.69 0.92 |
| WBC | < 20 / > 20 × 109/l | 18/13 | 13/10 15/11 |
5/3 3/2 |
1.00 0.92 |
| PR | GPR/PPR | 25/6 | 19/4 21/5 |
6/2 4/1 |
0.63 0.97 |
| Day 15 of induction | M1/M2/M3 | 25/2/4 | 20/1/2 22/1/3 |
5/1/2 3/1/1 |
0.32 0.33 |
| Day 33 of induction | M1/M2/M3 | 30/1/0 | 23/0/0 25/1/0 |
7/1/0 5/0/0 |
0.26 0.66 |
| RG | SR/IR/HR | 8/14/9 | 6/11/6 8/11/7 |
2/3/3 0/3/2 |
0.81 0.35 |
| M.C. | yes/no | 7/24 | 5/18 6/20 |
2/6 1/4 |
0.85 0.88 |
| Relapse/AML | yes/no | 11/20 | 4/19 6/20 |
7/1 5/0 |
0.006 0.004 |
F – female; M – male; WBC – initial white blood count; PR – prednisone response on day 8 of treatment; GPR – good prednisone response; PPR – prednisone poor response; M1 < 5% of blasts in bone marrow; M2 – 5–25% of blasts in bone marrow; M3 > 25% of blasts in bone marrow; M.C. – co-expression of myeloid antigens detected in flow cytometry; AML – transformation into acute myeloid leukaemia